Fusion Antibodies Pays Executive Bonuses in Shares as Part of Cost-Conscious Strategy

Fusion Antibodies Plc ( (GB:FAB) ) just unveiled an update.

Fusion Antibodies plc has issued 308,720 new ordinary shares to chief executive Adrian Kinkaid and chief scientific officer Richard Buick in lieu of a portion of their bonuses for the year to 31 March 2025, using the 13p issue price set in its recently announced £1.4m fundraise, as the company continues to prioritise cash conservation. Following the share-based awards, which represent part of reduced bonus entitlements and were approved under existing shareholder authorities, Kinkaid and Buick’s holdings rise to 0.83% and 0.90% respectively of the enlarged share capital, with total voting rights increasing to 125,021,878 shares upon admission of the new stock to AIM expected around 30 January 2026, clarifying the ownership base for investors and aligning senior management further with shareholder interests.

The most recent analyst rating on (GB:FAB) stock is a Hold with a £13.50 price target. To see the full list of analyst forecasts on Fusion Antibodies Plc stock, see the GB:FAB Stock Forecast page.

Spark’s Take on GB:FAB Stock

According to Spark, TipRanks’ AI Analyst, GB:FAB is a Neutral.

Fusion Antibodies Plc’s overall stock score is primarily impacted by its weak financial performance and concerning valuation. While there is some technical momentum, the negative P/E ratio and lack of profitability are significant risks. The absence of earnings call data and corporate events limits additional insights.

To see Spark’s full report on GB:FAB stock, click here.

More about Fusion Antibodies Plc

Fusion Antibodies plc is a Northern Ireland-based contract research organisation specialising in pre-clinical antibody discovery, engineering and expression services across human and veterinary therapeutics and diagnostic applications. The company provides an integrated end-to-end offering, including antibody discovery, characterisation, optimisation, humanisation via its proprietary CDRx platform, antigen design and expression, purification, sequencing and cell line development, and has completed thousands of antibody sequencing and expression projects and over 290 humanisation projects for a global client base that includes eight of the world’s top 10 pharmaceutical companies. Its strategy focuses on accelerating and improving the success of therapeutic antibody development in a rapidly expanding global antibody therapeutics market, while also targeting diagnostic and emerging veterinary sectors for additional growth.

Average Trading Volume: 843,964

Technical Sentiment Signal: Buy

Current Market Cap: £15.34M

Find detailed analytics on FAB stock on TipRanks’ Stock Analysis page.